1645-24-5

Basic information

• Product Name: 4-(4-Fluorobenzoyl)isophthalic Acid
• Synonyms: 4-(4-Fluorobenzoyl)-1,3-benzenedicarboxylic Acid;4-(4-Fluorobenzoyl)isophthalic Acid;4-(p-Fluorobenzoyl)isophthalic Acid
• CAS NO: 1645-24-5
• Molecular Formula: C₁₅H₉FO₅
• Molecular Weight: 288.23
• Product Categories: Aromatics Compounds;Aromatics;Intermediates;Aromatics, Intermediates
• Mol File: 1645-24-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 559.244°C at 760 mmHg
• Flash Point: 292.02°C
• Appearance: /
• Density: 1.464g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.629
• Solubility: Dimethyl Sulfoxide
• CAS DataBase Reference: 4-(4-Fluorobenzoyl)isophthalic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Fluorobenzoyl)isophthalic Acid(1645-24-5)
• EPA Substance Registry System: 4-(4-Fluorobenzoyl)isophthalic Acid(1645-24-5)

Safety Data

• Hazardous Substances Data: 1645-24-5(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 1645-24-5 differently. You can refer to the following data:
1. An intermediate for the preparation of Citalopram
2. An intermediate for the preparation of Citalopram.

InChI:InChI=1/C15H9FO5/c16-10-4-1-8(2-5-10)13(17)11-6-3-9(14(18)19)7-12(11)15(20)21/h1-7H,(H,18,19)(H,20,21)

Upstream product

• 352-13-6 4-flourophenylmagnesium bromide 
• 15764-16-6 2,4-dimethylbenzaldehyde 
• 356040-80-7 (2,4-dimethylphenyl)(4-fluorophenyl)methanol 

Downstream Products

• 335612-71-0 5-hydroxymethyl-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran 
• 372941-51-0 6-carboxy-3-(4-fluorophenyl)phthalide 

Relevant articles and documents

COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR

The invention relates to the field of pharmaceutical chemistry. Specifically, the present invention relates to a series of BET (bromodomain and extra-terminal domain) inhibitors having a novel structure, particularly inhibitors targeting BRD4 (Bromodomain-containing protein 4), and a preparation method and use therefor. The structure thereof is shown in the following general formula (I). Said compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or crystal form thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical compsosition thereof can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.